2010
DOI: 10.1186/1471-2407-10-468
View full text
|
|
Share

Abstract: BackgroundGlioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3).MethodsWe investigated MRP3 by genetic and immunohistochemical (IHC) analysis of human gliomas to determine the incidence, distribution, and localization of MRP3 antigens in …

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
26
0
1

Publication Types

Select...

Relationship

0
0

Authors

Journals